Needham Downgrades Pacira Biosciences to Hold From Buy

MT newswire2026/10/08 15:57

11:57 AM EDT, 10/08/2026 (MT Newswires) -- Pacira Biosciences (PCRX) has an average rating of overweight and mean price target of $31.06, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us) Price: 36.29, Change: +11.09, Percent Change: +43.99

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq

Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.

智通财经•2026/11/09 06:12

UniCredit: Third-quarter net profit reaches 3.26 billion euros, exceeding expectations

格隆汇•2026/11/09 06:11

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45